Newsbenzinga
Sanofi Says Japan Approves Wayrilz For Persistent Or Chronic Immune Thrombocytopenia Based On LUNA 3 Phase 3 Study
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…